Trial backs rituximab for maintenance of ANCA-associated vasculitis remission

Infusions of rituximab proved superior to the standard of care, daily oral azathioprine, at maintaining remission of ANCA-associated vasculitis in a randomized trial.

At final follow-up after 28...